NCI-designated subspecialist reviews improve 94% of pancreatic cancer treatment paths

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study published in Journal of Personalized Medicine explores how oncology subspecialist reviews of pancreatic adenocarcinoma cases can identify care gaps and provide recommendations intended to improve treatment outcomes. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
Researchers at Moffitt Cancer Center have published a case study highlighting the potential optimization of the TAMP, or trans-arterial micro-perfusion, procedure with RenovoCath to deliver intra-arterial gemcitabine (a commonly used chemotherapy) directly near a tumor (rather than traditional systemic IV administration) in a patient with locally advanced pancreatic cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login